Related Experiment Video
Updated: Dec 26, 2025
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
miR-1258: a novel microRNA that controls TMPRSS4 expression is associated with malignant progression of papillary
1Department of Endocrinology, The Second Hospital of Jilin University, Changchun, Jilin, China.
Background:
MicroRNA-1258 (miR-1258) has been shown to play an anti-cancer role in a variety of cancers, but its relationship with papillary thyroid cancer (PTC) has not been reported. The emphasis of this research was to reveal the biological function of miR-1258 in PTC and its potential mechanisms.
Material And Methods:
We measured miR-1258 expression in PTC cells and the transfection efficiency of miR-1258 mimic and miR-1258 inhibitor by quantitative real-time PCR (qRT-PCR) assay. Cell Counting Kit-8 assay (CCK8) and Transwell experiments were conducted to examine the influences of altering miR-1258 expression on the viability, migration, and invasion of PTC cells. Bioinformatics prediction and dual-luciferase experiment were performed to verify the target gene of miR-1258. Finally, we carried out a rescue assay to verify whether the regulation of miR-1258 on the biological behaviour of PTC cells needs to be achieved by regulating TMPRSS4.
Results:
The outcomes revealed that miR-1258 was lowly expressed in PTC cell lines and miR-1258 showed the lowest expression in KTC-1 and the highest expression in B-CPAP among all tested PTC cell lines. Overexpression of miR-1258 inhibited KTC-1 cell viability and ability to migrate and invade, whereas inhibition of miR-1258 in B-CPAP cells has the opposite effect. Furthermore, we affirmed that miR-1258 can directly target TMPRSS4, and miR-1258 can reduce the biological malignant behaviour of PTC cells via regulation of TMPRSS4.
Conclusion:
Taken together, our research raised the possibility that miR-1258 was an anti-oncogene, which exerts its anti-cancer function by targeting TMPRSS4. Hence, it may be possible to treat PTC by targeting the miR-1258/TMPRSS4 axis in the future.
Insights
MicroRNA-1258 (miR-1258) acts as an anti-oncogene in papillary thyroid cancer (PTC). It suppresses tumor cell viability, migration, and invasion by targeting TMPRSS4, suggesting a potential therapeutic target.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- MicroRNA-1258 (miR-1258) demonstrates anti-cancer properties in various malignancies.
- The specific role of miR-1258 in papillary thyroid cancer (PTC) remains uninvestigated.
- This study aimed to elucidate the function and mechanisms of miR-1258 in PTC.
Purpose of the Study:
- To investigate the expression levels of miR-1258 in PTC.
- To determine the functional impact of miR-1258 on PTC cell behavior (viability, migration, invasion).
- To identify and validate the direct target of miR-1258 in PTC and its regulatory role.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) for miR-1258 expression analysis.
- Cell Counting Kit-8 (CCK8) and Transwell assays to assess cell viability, migration, and invasion.
- Bioinformatics prediction, dual-luciferase assays, and rescue experiments to confirm target gene and mechanism.
Main Results:
- miR-1258 was found to be downregulated in PTC cell lines, with lowest expression in KTC-1 and highest in B-CPAP.
- Overexpression of miR-1258 inhibited KTC-1 cell viability, migration, and invasion.
- Inhibition of miR-1258 in B-CPAP cells showed opposite effects, confirming its tumor-suppressive role.
Conclusions:
- miR-1258 functions as an anti-oncogene in PTC by directly targeting TMPRSS4.
- The anti-cancer effects of miR-1258 in PTC are mediated through the regulation of TMPRSS4.
- Targeting the miR-1258/TMPRSS4 axis presents a potential future therapeutic strategy for PTC.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
02:23Abnormal Proliferation
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...